



Cloxacillin Sodium Powder

Therapeutical category:

Oral, narrow spectrum penicillin

Characteristics:

A crystalline powder, hygroscopic



Applications:

The product is suitable for the manufacture of powders and granules for oral suspension.

All our manufacturing sites use the best available technology and operate dedicated waste water treatment plants, 24/7 throughout the year. Effluents are regularly sampled and checked for antimicrobial activity.

Quality



Reliability



Sustainability



Key parameters: Cloxacillin Sodium Powder

Pharmacopeia quality	USP, EP, IP	
Regulatory information	EU: EDQM India: MoH Bangladesh: MoH	Japan: PMDA Australia: TGA
Appearance	White or almost white crystalline powder, hygroscopic	
Assay (anhydrous basis)	Cloxacillin: 95.0–102.0 %	
pH	5.0 – 7.0	
Water	3.0 – 4.5 %	
Tapped bulk density	≥ 0.28 g/ml	
Total impurities	≤ 5.0%	
Residual solvents	2-EHA: ≤ 8000 ppm Ethyl acetate: ≤ 9500 ppm	
Dimethylaniline	Not used in the process	
Shelf-life	Minimum 4 years in the original packaging under storage conditions	
Batch size	Approximately 1000 kg	
Storage conditions	Below 25°C, protected from light and moisture	
Packaging	Primary packaging: polyethylene bag	
	Secondary packaging: thermo-sealed aluminum polyethylene bag	
	Outer packaging: corrugated box or HDPE drum	
	Fixed quantity of 25 kg packed in each bag	

Contact and information

For more information, please visit www.centrient.com or e-mail: info@centrient.com or contact us at one of the addresses below:

Rotterdam (HQ)
sales@centrient.com

Europe/North America
Delft, The Netherlands
sales.ea@centrient.com

Asia Pacific / Middle East / Africa
Gurgaon, India
sales.amea@centrient.com

China
Beijing, P.R. China
sales.china@centrient.com

Mexico & Latin America
Ramos Arizpe, Mexico
sales.mla@centrient.com

Copyright © 2019 Centrient Pharmaceuticals. All rights reserved. Although diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein can be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor can it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement.

The content of this document is subject to change without further notice. Please contact us for the latest version of this document or further information. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions like the Bolar provisions in the US and 2004/27/EC in Europe.

VAPFS 2019